GSK, Pfizer RSV vaccine sales fall in US
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
GSK RSV shot 43% effective against severe disease in third year
WEB18 hours ago · That compares with 94.1% effectiveness in preventing severe RSV in the first season and 64.2% a year later, according to data from GSK's Phase 3 clinical trial.
See results only from reuters.comGSK's experimental drug sho…
May 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal …
GSK presents positive data for AREXVY, its respiratory syncytial …
WEB1 day ago · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a …
GSK Says RSV Vaccine Offers Protection Over Three Seasons
WEB18 hours ago · 1:42. GSK Plc’s shot for respiratory syncytial virus provided protection across three seasons after vaccination, the company said Tuesday. The shot for older …
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK raises profit outlook on strong vaccine, HIV drug sales
WEBMay 1, 2024 · GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to slow in the second half.
GSK's experimental drug shows promise in reducing …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker...
- People also ask
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, …
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the …
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with …
New GSK to deliver step-change in growth and performance over …
WEBJun 23, 2021 · At an update to investors today, GlaxoSmithKline plc (GSK LSE & NYSE) will provide details of its strategy, outlook for growth and plans to create shareholder …
GSK to acquire clinical-stage biopharmaceutical company …
WEBMay 31, 2022 · GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones. Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology.
Related searches for gsk glaxosmithkline news
